February 2019

Letter from the Editor

February 1, 2019

Agile Transformation By definition change is hard, and anyone who works for a large or even a small company has been through at least one reorganization. The agility that companies will need to compete in the new economy, one defined by the digitization of healthcare, cannot be underestimated, and requires previously unexperienced reorganization of priorities […]

Upfront

February 1, 2019

Bayer Ups its Pledge for Science Learning Experiments For Children Bayer has pledged 5 million hands-on science learning experiments for children in the United States by 2025. The milestone, if achieved, will correspond with the 30th anniversary of Bayer’s award-winning commitment to science, technology, engineering and mathematics (STEM) education in the United States. Bayer also […]

Health Tech

February 1, 2019

POPS! Blood Glucose Test Attaches To Smartphone Trend Watch: Medical Devices Support Patient Monitoring from Head to Toe Minneapolis-based POPS! Diabetes Care received FDA clearance for its blood glucose monitoring system that can be adhered to the back of a smartphone. Readings are taken via built-in needles that prick the thumbs, and a sensor absorbs […]

Innovator’s Corner

February 1, 2019

Harnessing the Power of the Body’s Electrical System Frank Amato, CEO of electroCore, talks about how vagus nerve stimulation can be used for the preventive treatment of cluster headache and for the relief of pain associated with migraine and episodic cluster headache. Our nervous system interacts with a variety of different things in our bodies, […]

Artificial Intelligence

February 1, 2019

Bayer Uses AI to Boost Pharmacovigilance Trend Watch: Pharma Use of AI Increases In an effort to accelerate its patient safety data monitoring by using artificial intelligence, Bayer has partnered with Genpact to employ its Pharmacovigilance Artificial Intelligence (PVAI) products. These AI tools will be added to Bayer’s existing pharmacovigilance database and IT systems and […]

Last Word

February 1, 2019

Defining Your Career Path Dagmar Rosa-Björkeson, chief strategy and corporate development officer, Mallinckrodt Pharmaceuticals, gave the keynote address at the BioNJ Inspiring Women in Stem meeting, held in December 2018. PharmaVOICE caught up with her after the event. PV: What advice do you have for women who are interested in advancing their careers? Rosa-Björkeson: First, […]

Transformation: Ready, Set, Agile

February 1, 2019

According to McKinsey, companies that have enterprise agility share some commonalities: a North Star-mentality, in other words an overarching customer strategy; a scalable team structure; a rapid decision-making mentality; a dynamic people model that ignites passion; and a willing adoption of next-generation technologies. In today’s environment, one in which companies find themselves having to transition […]

SHOWCASE: Outsourcing – M&A on the Rise

February 1, 2019

Pharmaceutical outsourcing remains big business, as companies cut internal costs and with the rise of smaller specialist companies focused on rare diseases and genomics-based therapies. The move to outsource is growing, with reports that companies are turning to partners more now than they did five years ago. This has led to a steep rise in […]

Outsourcing Regulatory Filings with an FTE Model: Five Keys to Consider

February 1, 2019

As an increasing number of drug and device developers focus their efforts on reducing costs so they can invest more heavily in their core R&D functions, it’s no surprise that the outsourcing market for healthcare regulatory affairs is predicted to expand at a rapid pace over the next decade. Some estimates say the market will […]

SHOWCASE: Rare Disease: Rare Difficulties: Finding Cures and Tackling Costs

February 1, 2019

The day-to-day lives of people with rare diseases is often poorly understood. And those with rare diseases face many challenges. Whether it’s going to work or studying, completing daily tasks such as preparing meals and shopping, or simply managing their health, the impact disease has on patients can be overwhelming. Since the Orphan Drug Act […]

Raising One Voice for the Millions Impacted by Rare Disease

February 1, 2019

Next-generation technologies in medicine have opened new doors for identifying rare diseases and developing better and more targeted rare disease treatments. Remarkable advancements in global research efforts have already made an impact on the lives of patients living with hundreds of rare disease types, especially due to the recent exponential growth in approved treatment options […]

Is the Rare Disease Business Model Here to Stay?

February 1, 2019

These days, the term “rare disease” is well ingrained in our everyday vernacular — but that hasn’t always been the case. The pharmaceutical industry paid little attention to developing new treatments for rare disease prior to the Reagan Administration’s implementation of the Orphan Drug Act (ODA) in 1983, which provided incentives for pharmaceutical companies to […]

From Scientific Discovery to Real World Application: the “Future” of Medicine is Here

February 1, 2019

I vividly remember the day in February of 2001 when the nearly complete sequence of the human genome was first published. My cellular and molecular biology professor had unfolded a giant poster from the journal Nature and revealed those approximately 30,000 genes to our class. Amazingly, in less than two decades since that seminal moment […]

Executive Perspective: A Fused Model for the Enterprise – A Conversation with Brian Williams

February 1, 2019

Winning in today’s digital era requires more than just apps and a website. Fusing an enterprise for success in the digital era requires companies to seamlessly collaborate across the enterprise and create a true strategic pathway for a better customer experience. Recently, Cognizant commissioned a comprehensive study conducted by Forrester to test the hypothesis that […]

Red Zone: Disruptive Innovation: Questions for the C-Suite

February 1, 2019

It is not the strongest of the species that survives, nor is it the most intelligent. It is the one that is most adaptable to change. Whether a direct quote from Charles Darwin or a summary of his writings, this statement is perhaps the most profound scientific explanation of life itself, in all its shapes, […]

FEEDBACK